• Hanneke Buter, Matty Koopmans, and van der Voort Peter H J PHJ Dept. of Intensive Care, OLVG, Amsterdam, the Netherlands; TIAS School for Business and Society, Tilburg University, Tilburg, the Netherlands..
• Dept. of Intensive Care, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
• J Crit Care. 2018 Oct 1; 47: 88-92.

PurposeTo determine the effect on strong ion difference of citrate as an anticoagulant during continuous veno-venous hemofiltration (CVVH).Materials And MethodsICU patients with renal failure and CVVH were included. Patients were treated with either nadroparin (N) or sodium citrate (C) as an anticoagulant. Strong ion difference (SID) apparent (SIDa) and SID effective (SIDe) and strong ion gap (SIG) were calculated at t = 0 and t = 24 h. Citrate concentration was measured in the citrate treated patients.ResultsTen patients with N and nine with C were included. In both groups the SIDa did not change significantly. SIG decreased significantly with N (11.4 ± 4.2 to 4.0 ± 3.1 meq/l; p = 0.005) but not with C (9.3 ± 1.9 to 8.1 ± 2.4 meq/l; p = 0.097). The decrease was significantly greater for N compared to C; p = 0.014. This is reflected by the SIDe which increased significantly (p = 0.022) more from 24.7 ± 4.5 to 32.9 ± 3.9 (p = 0.005) for N and from 26.3 ± 5.8 to 29.6 ± 1.6 for C (p = 0.058).ConclusionCitrate anticoagulation results in a persistently high SIG during CVVH compared to nadroparin. This is associated with the presence of unmeasured anions such as citrate in the systemic circulation.Copyright © 2018 Elsevier Inc. All rights reserved.

33 keywords...

hide…